Results:
The multivariate analysis for both groups shows a pvalue of 0.452 to obtain the probability for DHI > 0,75 and a p-value of 0.897 to obtain a probability for HI>0.70. In Figure  1 , the plots of the results are presented:
Conclusion: According to dose homogeneity, the analysis states that there were no significant differences for both studied groups. These results suggest the possibility of increasing the boost dose in T3b patients 
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Material and Methods:
From August 2012 to September 2015, 113 patients underwent a single-fraction HDRBT boost of 15 Gy using real-time TRUS based planning. External beam radiation therapy (EBRT) (37.5 Gy/15f or 44Gy/22f or 45Gy/25f) was performed before (30%) or after (70%) HDRBT boost. We analyzed prostate, urethra and rectum dosimetrics data. Genito-Urinary (GU) and Gastro-Intestinal (GI) toxicity were assessed 4 and 12 months after the end of combined treatment using the International Prostate Symptom Score Scale (IPSS) and the Common Terminology Criteria for Adverse Events (CTCAE) v3.0.
Results: Prostate D90 between 105% and 115% was achieved for 99% of patients, prostate V150 ≤ 40% for 99%, prostate V200 < 11% for 96%, urethra D10 <120% for 99%, urethra V125= 0% for 100% and rectum V75<1cc for 95% of patients. Median IPSS score was 4 at the baseline and didn't change at 4 and 12 months after combined treatment. No patients developed ≥ grade 2 GI toxicity. With a median follow-up of 10 months, only two patients experienced biochemical failure. Cumulative percentage of patients with PSA ≤ 1 at 4 and 18 months was respectively 47% and 74 %.
Conclusion:
Single-fraction HDRBT boost of 15 Gy using realtime TRUS based planning in combination with EBRT is a safe treatment with promising results. A longer follow-up is needed to assess long-term outcome and toxicities Purpose or Objective: The aim of this study was to evaluate the acute and late toxicities and disease-specific and overall survival after interstitial brachytherapy for the treatment of gynecological and digestive tumors.
Material and Methods:
A retrospective study was carried out on a series of 19 patients referred for interstitial brachytherapy in our center between 2008 and 2013 with histologically proved locally advanced or recurrent gynecological malignancies and digestive tumors. Patients with distant metastases were excluded. Treatment consisted of brachytherapy alone (5p) (gynecological recurrence and anal carcinoma), or after surgery (1p) (rectal carcinoma) or after surgery and radiochemotherapy (4p) or after radiochemotherapy (9p). The radiochemotherapy with cisplatin-based chemotherapy regimens. Previously, recurrent patients (4p) were been treated with radiotherapy with or without concurrent chemotherapy. Medium dose of external beam radiotherapy was 51,7 Gy (range 45-70 Gy) followed by interstitial brachytherapy median implant dose 22,3 Gy (range 9-38,5Gy). Inclusion criteria were as follows: Hb minimum 10gm/dl and performance status 70% or more.
Results:
Median age was 59 years (range 36-82). With a median follow-up of 14 months, local control was achieved on clinical examination or magnetic resonance imaging 93,8% patients. Among 19 patients studied, 3 lost follow-up and they were excluded from late toxicities and survival analysis. Eleven of the 19 patients (57,9%) experienced Radiation Therapy Oncology Group (RTOG) grade I or II acute toxicities proctitis (36,3%), cystitis (81,8%) and ephitelitis (18,2%). Not acute toxicities grades 3 or 4 were reported. Two of the 16 patients (12,5%) experienced RTOG grade I or II late toxicities proctitis (6,25%) and cystitis (6,25%). Two of the 16 patients (12,5%) experienced RTOG grade III or IV late toxicities rectal ulcer (6,25%) and vulvar necrosis (6,25%). Using Kaplan-Meier analysis overall survival after minimum follow-up of 14 months was 93% and disease-free survival was 75% (persistent tumor were included in this group). One patient had a locoregional recurrence and died of tumor.
Conclusion:
Interstitial brachytherapy is a good choice to deliver high-dose radiation in gynecological tumor after external beam radiotherapy or as an exclusive treatment in S952 ESTRO 35 2016 _____________________________________________________________________________________________________ recurred and previously radiated digestive tumors. This treatment offers adequate locoregional control with acceptable range of complications. Purpose or Objective: To study normal skin acute toxicity in Non-Melanoma Skin Cancer (NMSC) patients treated with High Dose Rate (HDR) Plesiotherapy and very high viscosity addition silicone (VHVAS) rubber custom-made molds. VHVAS rubber features excellent mechanical and physical properties which benefit the stability and reproducibility of the implant. On the other hand, the high electron density relative to water of these materials will increase the scatter production, which may be relevant at the mold-skin interface. [2] [3] [4] [5] . Standard fractionation is 5.5 Gy/fr, 10-12 fr, twice a week. Acute toxicity was retrospectively assessed following the RTOG criteria.
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EP-2015 Acute toxicity in HDR BT of skin cancer with very high viscosity addition silicone custom made molds
Material and
Results: DVH analysis showed high dose areas having: D1cc= 8.5 Gy/fr [5.4-14.4 ], D0.5cc= 9.0 Gy/fr [5.4-16 .3], D0.1cc = 10.3 Gy/fr [6.2-22.9]. All patients presented radiodermatitis 1 month after treatment (G2: 89%, G3: 11%). 32% presented radiodermatitis at 3 months (G1: 26%, G2: 6%) and only one patient presented radiodermatitis G1 at 6 months. Toxicity score correlation to CTV volume, treatment depth, BED prescribed dose, D1cc, D0.5cc and D0,1cc had no statistical significance (p>0.05). Treated area was found to be predictive of radiodermatitis persistence at 3 months after treatment (p=0.036). Lesions located in the legs showed longer recovery time from radiodermatitis than other locations (4 months vs 1.8 months average).
Conclusion:
The use of these VHVAS moulds was welltolerated by all patients. Our treatments yield similar results to other groups with similar treatment schemes in terms of acute toxicity. We can conclude that VHVAS custom made molds have a good safety profile. 
EP-2016 A method to transform 2D LDR brachytherapy plans into contemporary 3D PDR dose distributions E. Rodenburg
